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The effect of transcranial direct current stimulation (tDCS) is cumulative. Treatment
protocols typically require multiple consecutive sessions spanning weeks or months.
However, traveling to clinic for a tDCS session can present an obstacle to subjects
and their caregivers. With modified devices and headgear, tDCS treatment can be
administered remotely under clinical supervision, potentially enhancing recruitment,
throughput, and convenience. Here we propose standards and protocols for clinical
trials utilizing remotely-supervised tDCS with the goal of providing safe, reproducible
and well-tolerated stimulation therapy outside of the clinic. The recommendations
include: (1) training of staff in tDCS treatment and supervision; (2) assessment of
the user’s capability to participate in tDCS remotely; (3) ongoing training procedures
and materials including assessments of the user and/or caregiver; (4) simple and
fail-safe electrode preparation techniques and tDCS headgear; (5) strict dose control
for each session; (6) ongoing monitoring to quantify compliance (device preparation,
electrode saturation/placement, stimulation protocol), with corresponding corrective
steps as required; (7) monitoring for treatment-emergent adverse effects; (8) guidelines
for discontinuation of a session and/or study participation including emergency failsafe
procedures tailored to the treatment population’s level of need. These guidelines are
intended to provide a minimal level of methodological rigor for clinical trials seeking
to apply tDCS outside a specialized treatment center. We outline indication-specific
applications (Attention Deficit Hyperactivity Disorder, Depression, Multiple Sclerosis,
Palliative Care) following these recommendations that support a standardized framework
for evaluating the tolerability and reproducibility of remote-supervised tDCS that, once
established, will allow for translation of tDCS clinical trials to a greater size and range of
patient populations.
Keywords: tDCS, clinical trials, attention deficit hyperactivity disorder, depression, multiple sclerosis, palliative
care
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Introduction
Transcranial direct current stimulation (tDCS) is a noninvasive
brain stimulation (NIBS) technique that utilizes low amplitude
direct currents (typically less than 2.5 mA current and
0.08 mA/cm2 average electrode current density) to induce
changes in cortical excitability. Advantages of tDCS compared
to other methods of NIBS, such as transcranial magnetic
stimulation (TMS), include ease-of-use, low cost, and tolerability
(Vanneste et al., 2010). Using clinical grade equipment and
following strict protocols with trained operators, tDCS has been
tested in hundreds of clinical trials and is considered to be both
safe and well-tolerated for study in a wide range of subjects
(Nitsche et al., 2008; Brunoni et al., 2012b; Kalu et al., 2012).
tDCS can influence sensory, motor, cognitive and psychiatric
processes that could be applied directly to the treatment of
common yet refractory symptoms that represent major areas of
unmet treatment need, such as depressed mood, pain, fatigue,
sensory and motor recovery, and cognitive impairment (Ball
et al., 2002; Fregni et al., 2006; Mori et al., 2010, 2013; Andrews
et al., 2011; Acler et al., 2013; Brunoni et al., 2013b; Cuypers et al.,
2013; Bennabi et al., 2014), typically occurring in the context of a
neurologic or psychiatric condition.
Remote Delivery Will Expand tDCS Clinical Study
Neurophysiologic and clinical trials with tDCS increasingly
reinforce that efficacy increases with multiple sessions (Mori
et al., 2010, 2013; Acler et al., 2013; Ferrucci et al., 2014;
Meesen et al., 2014; Tecchio et al., 2014), with effects thought
to be cumulative. Many clinical investigators apply tDCS in
conjunction with a behaviorally-based treatment approach to
improve outcome (Demirtas-Tatlidede et al., 2013; Martin et al.,
2013b; Brunoni and Vanderhasselt, 2014; Brunoni et al., 2014;
Flöel, 2014), which must be repeated alongside tDCS. The
clinical utility of tDCS must be established through trials that
are sufficiently-powered, with adequate dose (Peterchev et al.,
2012) and session number, and with precise protocol control.
However, multiple sessions require subjects to repeatedly travel
to the clinic for each treatment, placing significant and often
insurmountable burden to patients and their caregivers, at the
same time associated with significant provider time and cost,
especially as the sample size increases (Brunoni et al., 2012a;
Holland and Crinion, 2012; Ferrucci et al., 2014; Meesen et al.,
2014; Shiozawa et al., 2014; Vaseghi et al., 2014). For example,
in a sample of 64 subjects treated for depression, Loo et al.
administered 30 sessions across 6 weeks (Loo et al., 2012),
followed by up to 20 maintenance treatment sessions spaced over
6 months (Martin et al., 2013a). Similarly, during the 6 month
follow up of a depression trial, Valiengo and colleagues showed
a dropout rate of 17 of 42 subjects---with almost all dropouts
citing the burden of regular visits to the clinic (Valiengo et al.,
2013).
A remedy to this feasibility problem is controlled remote
tDCS application, with a common protocol that ensures
safe, well-tolerated and reproducible remotely-supervised tDCS.
Combining this remote approach with behaviorally-based
treatments (e.g., cognitive or physical rehabilitation exercises
completed at home, or behavioral therapy delivered through
remote, web-based platforms) will allow investigators to reach
subjects either through satellite clinic locations or directly from
their home or care facility.
While there has not yet been a clinical trial involving
remotely-supervised tDCS, the home use of tDCS over a 3 year
period has been reported as both safe and effective in the case
of a patient with schizophrenia through 20 minute daily sessions
administered by a medically licensed caregiver (Andrade,
2013).We propose here a protocol for remotely-supervised
delivery of tDCS for clinical trials, with the expectation of
maintaining the same level of uniformity and compliance that
would be seen with tDCS sessions administered in the clinic.
This step represents an extension of currently-accepted tDCS
methodology to allow for trials to include more subjects and
to remove any logistical limits on the number of sessions
studied.
The approach proposed for remotely-supervised tDCS can
be applied to double-blind trials. tDCS clinical trial devices
have been developed which deliver active or sham stimulation
depending on the individual subject code keyed in, leaving both
device operator and subject blinded to treatment assignment.
There is no reason why blinding should be any less available
when the subject (or proxy) operates the device under remote
supervision.
The Potential and Limitations of tDCS Away
From Clinic
Below, we outline a set of what we consider to be essential
features for this next step of remotely-supervised tDCS delivery.
While the tDCS may be self- or proxy-administered, an
important distinction is the difference with this controlled and
remotely-supervised extension as compared to direct home
use. One recent report described the challenges of prescribing
tDCS directly for self-administered home use, without remote
supervision. Using a crossover design to treat pain in patients
with trigeminal neuralgia, investigators (Hagenacker et al., 2014),
instructed subjects and one other adult to apply tDCS at home
using a device pre-programmed to alternate active and sham
stimulation across 14 sessions over 2 weeks, recording any
adverse effects in a diary. All subjects tolerated the stimulation
well with no adverse events reported; active treatment was found
to be effective in reducing pain. However, many subjects reported
difficulty with the tDCS application with an associated high
dropout rate (41%). The authors concluded that a more specific
and detailed education and training protocol could improve
delivery. Of further concern, there was minimal guidance or
structure during the course of sessions, possibly leading to
variability of method across subjects and no explicit safety
monitoring.
It is clear that a structured protocol is needed to identify
subjects who are appropriate candidates for remote study, and
to ensure that they---or a proxy who will administer the tDCS
for them (e.g., caregiver)---are adequately trained. This training
and certification, must be gauged against the usability of the
(specially-designed) device and headgear, the likelihood that
the subject may fluctuate in ability to operate the equipment
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(e.g., due to fluctuations in physical or mental state), the risks
associated with the specific trial, and other relevant study factors
such as the nature of ongoing monitoring.
As a qualifier, specialized equipment designed for this remote
study purpose is a minimum requirement. State-of-the-art
clinical tDCS equipment and accessories have been developed
and validated in controlled clinical trials, with trained operators.
It is not safe or prudent to simply provide subjects with
specialized clinical equipment, including devices and headgear,
not designed for home use. Doing so without accounting for
variability in skill, training, and environment puts subjects at
risk and compromises reproducibility (e.g., dose control). The
distinction betweenmedical equipment designed for professional
operators vs. subjects and their caregivers is evident across
physical medicine, and is no less important for tDCS. It is
misguided to conflate the inherent simplicity and tolerability of
clinical tDCS with the assumption that devices not designed for
subject use applied by untrained operators pose no risk (Bikson
et al., 2013) and allow for reproducible protocols (Peterchev et al.,
2012).
Our guidelines are built around ongoing supervision in real-
time, even with subjects who have completed training and
demonstrated competency to self-administer. While the level of
supervision may vary across patient group or risk level at the
subject level, we believe that consistency is essential for every
tDCS session to ensure safety and tolerability, as well as to
maintain the standards of administration set by tDCS sessions
in the clinic.
Requirements for Remotely-Supervised
tDCS: Essential Features
The recommendations listed here are governed by the principle
that remote tDCS administration must be safe, structured and
reproducible across study sites. Items are generally categorized by
training of staff and subjects/caregivers, design of headgear and
stimulators, and ongoing monitoring. These items are interrelated
and are itemized here for emphasis of key points---in clinical trial
design they will be implemented holistically.
Training of the tDCS Research Staff
Study research staff will first be trained in tDCS treatment
technique and in administering tDCS to others. Staff will be
trained using standard-operating-procedures (SOP) specifying
all subject interactions as well as device usage. In terms of
subject interaction, study research staff will be trained to monitor
for study-specific ‘‘stop’’ criteria following a decision-tree-based
flowchart that allows for evaluation of eligibility to continue at
each progressive step. At baseline visits (in clinic) tDCS research
staff will complete a checklist to screen subjects for at home tDCS
(see Figure 1 for an example).
Following training on screening procedures, study research
staff will be briefed on the usage of the device and the location
of headset placement. In addition, selected research staff will
be trained with and have access to a guide that details (e.g.,
the device manual), in a step-by-step fashion, the procedures
that are required to configure and program devices prior to
FIGURE 1 | Example of subject checklist.
release to subjects, for example programming device unlock
codes for one-time use to be provided prior to each session.
Prior to releasing a device to a subject, selected research staff
must program the intensity, duration, and condition (active or
sham) of each planned session, along with code that limits the
number and frequency of sessions. In the case of code-based
session release, research staff will be instructed to withhold any
one-time use codes until subject device placement and setup are
deemed appropriate.
Research staff will be trained in the preparation and testing
of any devices and accessories (e.g., kits) release to subjects,
as documentation of material release. Through the duration
of the study, technicians will be trained to monitor subjects
for any unexpected adverse events (e.g., atypical discomfort) or
misuse of the device. At the end of the study, technicians will be
instructed on how to evaluate retrieved physical device materials
(e.g., headgear/stimulator condition, expendables) and download
any data stored on the device (e.g., completion codes for each
subject’s study sessions, stimulation history of each code issued)
as relevant to confirm compliance (Figure 2).
In addition to training specific to the implementation of
remotely-supervised tDCS as describe above, the clinical research
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FIGURE 2 | Guidelines for training.
team needs to be skilled in other aspects of clinical trial
methodology, including screening of subjects, monitoring of
subject progress and evaluation of outcomes.
Initial and Ongoing Assessment of the User’s
Capability to Participate in tDCS Remotely
A precisely defined protocol (decision-tree-based flowchart) will
be closely followed through the duration of the study for each
subject. Study ‘‘stop’’ criteria (Figure 3) will be reviewed at
each stage of the trial: screening, baseline, study sessions, and
follow-up. If stop criteria are met at any time throughout the
study, the session and/or trial participation will be terminated
as specified in the protocol. Following an initial screening,
at least one baseline visit will confirm the subject’s tDCS
aptitude and tolerability. Before any subject is sent home with
a device, it will be determined whether the subject-or designated
proxy- can properly follow the steps to ensure correct electrode
preparation and placement, low impedance and safe removal of
the device, and whether the subject can tolerate the stimulation
period.
Throughout the study, general compliance will be maintained
through stop criteria that exclude subjects who continually
fail to set up a device properly or fail to attend regularly
scheduled sessions. In addition, if any subject reports an
unexpected level of discomfort, pain, or desire to withdraw, the
session and/or ongoing study participation may be terminated.
At the end of the study, the record of completed and
uncompleted sessions, recorded by the device itself, will
be reviewed for all subjects who successfully met study
criteria. This will be used to determine both individual
subject and overall trial compliance based on pre-determined
criteria.
Supportive Training Procedures and Materials
(Including Assessments of the User and/or
Caregiver)
The protocol will be supported by a manual of operating
procedures for study staff. For designs with remote supervision
of self- or proxy-administered tDCS, that there be at least two
in-person training sessions with study staff, including training
and practice for the real-time remote supervision procedures
(e.g., a training session with a study staff member that includes
connection to another remotely-located study staff member via
secure internet-based video conference).
For subjects who meet criteria for study continuation,
subsequent sessions will be completed with the remote technician
alone, with the nature and length of ongoing monitoring to be
specific to the subject or trial. For instance, some subjects may
require remote monitoring indefinitely, while other trials may
use remote monitoring for a training period only.
The protocol will include sequential safety, tolerability
and compliance ‘‘stops’’ administered by the supervising
study staff throughout the course of the treatment sessions
to ensure appropriate use. For instance, potential concerns
include failure to place the headset and electrodes correctly,
selecting incorrect electrode polarity, inadequate electrode
saturation, lack of compliance, and loss of precision in electrode
placement.
Each subject will be provided with supportive and readily-
accessible training materials (Figure 2). These should include an
instruction manual (potentially supported with an instructional
video) and a method to self-report (electronic or binder). These
materials are designed as a resource to the subject to reference
or confirm study details. In addition, they serve the purpose
of remotely training subjects or caregivers who look to clarify
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FIGURE 3 | Example of study flowchart with stop criteria.
items of set-up or device usage. The self-report binder will
provide the subject with forms that measure adverse events,
assess tolerance, along with study-specific measures (e.g., mood).
While the manual and video (if used) will serve as ongoing
training procedures, the self-report forms will enable the subject
and caregiver to assess the experience throughout the study. Any
remotely-delivered adjunctive behavioral therapy (e.g., cognitive
or physical training) will be trial-specific with a supplemental
protocol and procedures.
Simple and Fail-Safe Electrode Preparation and
Positioning
The essential aspects of reproducible tDCS dose (defined in
Peterchev et al., 2012) are electrode preparation and montage
(addressed in this section) and waveform (addressed in the
next). Remotely-supervised tDCS administration would reduce
barriers to reliably apply tDCS away from the treatment
center.
The headgear should be designed to allow simple and
consistent placement of electrode at desired locations on the scalp
(Figures 4, 5)---for example headband snaps for the sponges to be
placed on the headband to ensure consistent correct placement.
Subjects will be screened for aptitude with the specific
headgear as part of inclusion/enrollment. Participation is
contingent on the ability to properly apply the headset and
correctly operate the device. The headgear may be marked in a
way that facilitates reliable setup, for example the headset will
be labeled ‘‘RED’’ and ‘‘BLACK’’ to confirm that color coded
cables are properly placed, ensuring anode (RED) and cathode
(BLACK) placement (white can be substituted for red if color
blindness is a concern). The headset should be designed to fit
reliably on the head, for example designed with a market to align
with the bridge of the nose at midline. Headsets may come in
multiple sizes and/or allow adjustment by research staff. The
device includes an impedance meter and will not allow access
until headgear and electrodes are accurately and correctly placed.
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FIGURE 4 | Example of hardware-based waveform control. Users are
provided with an individual device and accessories such as the 5x-Session
Home Kit (A)The subject checks in with the supervisor before and after each
session (B). The supervisor unlocks operation before each session by providing
a code (B). The subject enters only the code provided with no access to device
programming or stimulation settings. The subject uses custom fit headgear to
position electrodes (C,D). The device automatically collects compliance data
and may also prompt the user for information (E). Details of implementation will
be customized to each clinical trial while maintaining the principles of supervised
neuromodulation (F,G). (Image courtesy of Soterix Medical Inc.)
The headset should be designed tominimize error in electrode
placement, ideally allowing just the montage designed for the
specific trial (Figure 6), e.g., bifrontal montage (for dorsolateral
prefrontal cortex target application) or M1-SO montage (for
motor cortex target applications).
Subjects/proxies should be provided with kits which include
all of the necessary supplies for the entire study or until
expendable can be replenished (by either a visit to the clinic or
visit by study personnel to the subjects’ home or care-facility).
Components should be labeled properly in order to simplify
application, minimize confusion, and prevent error (e.g., mark
each pair of sponges by session number). The subject manual
should clearly explain the contents of the kit and the correct use
of each component.
Also of note, re-use of sponges across subjects is not hygienic.
Re-use of the sponge across sessions, even when cleaned, is
not recommended for supervised home use- single-use sponges
increase tolerability, cleanliness, and reproducibility. Medical
grade sponges are required to comply with biocompatibility
requirements, and labeling for re-use would require testing under
the intended conditions of use---which are complex and variable
in the case of home-application. Reliable control of cleanliness,
much less contamination, would prove difficult in home use
(would not for example be reliably detected by impedance check
or remote observation).In addition, attempt to remediate these
sponge re-use concerns would increase the operator and patient
burden for monitoring and preparation (e.g., concerns about
storage, residue from skin/hair product).
Strict Dose Control for Each Session
Control of stimulation parameters is the second essential aspect
after electrode placement. For tDCS essential parameters are the
intensity, duration (along with any ramp), and condition (active
or sham) of stimulation. For multiple sessions, the number
and interval of sessions is critical. For remotely-supervised
tDCS, limitations on the number and timing of sessions, along
with control of each session intensity and duration is pivotal
(Figure 6). Providing subjects with clinical stimulators that
do not limit either is not safe or supportive of reproducible
protocols.
Two general approaches to control stimulation parameters
under remotely supervised-tDCS can be considered. In the first
case, ‘‘hardware’’ based limitation (Figure 4) provides subjects
with equipment that is pre-programmed to provide a limited
number of sessions with limited interval. For example, the
stimulator will provide only 10 sessions, with pre-set intensity,
duration, and condition, with a maximum of one session every
23 h. Once 10 sessions have exhausted, the device no longer
provides output until the entire hardware or a component
(storage disk) is replaced. With ‘‘hardware’’ limitations, it
is not necessarily possible to remotely stop use before the
10 sessions are activated. The Soterix Medical/Neuroconn
Mobile transcranial Direct Current Stimulator (Mobile) and
Magstim/Neuronica HDC-Kit are example of ‘‘hardware’’ based
limitation. Subjects or caregivers are required to return to
the clinic to replenish expended hardware---supervisors may be
provide a ‘‘pack’’ containing multiple dose-control hardware
units (e.g., 10 storage disks with 10 sessions each for 100 sessions)
but this effectively extends the window where control of dose is
limited.
In the second case, ‘‘software’’ based limitation (Figure 5)
subjects are provided with a device which is deactivated
until a code is provided by the research staff. The code
typically unlocks a single session which a pre-set duration and
intensity. After a single discharge, the device is inert until
a new code is provided. This allows the remote supervisor
to tightly control compliance, for example not providing a
code until proper electrode set-up is confirmed by video,
Frontiers in Systems Neuroscience | www.frontiersin.org 6 March 2015 | Volume 9 | Article 26
Charvet et al. Remotely-supervised tDCS for clinical trials
FIGURE 5 | Example of software-based waveform control. Users are
provided with an individual stimulator, a discharge key, and accessories
such as the 5x-Session Home Kit. The supervisor limits stimulation by
programming the discharge key. The subject plugs the discharge key into
the device and presses a single button to activate stimulation. The subject
uses custom fit headgear to position electrodes. The device automatically
collects compliance data which is stored in the discharge key. Details of
device implementation will be customized to each clinical trial while
maintaining the principles of supervised neuromodulation. (Image courtesy
of Soterix Medical Inc.)
provides an opportunity for supervisor to directly interact with
subject and gather feedback and data for each trial. In this
situation, the remote supervisor may vary the provided code
based on subject experience. Soterix Medical transcranial Direct
Current Stimulator mini-Clinical Trials system (Mini-CT) is one
example of ‘‘software’’ based limitation. Given stimulators can
be programmed with excess of codes (e.g., thousands), there
is no need for subjects to return to the clinic to replenish
hardware.
In both ‘‘hardware’’ and ‘‘software’’ based governing for
remote supervision, the subject or caregiver does not program
session intensity of duration which enhances safety and
reproducibility. In case of blinded treatment, the subject may
not know which device/code is real or sham treatment. Double
blinding may also be implemented by blinding the remote
supervisor.
The user manual should clearly explain the hardware contents
of the kit and the correct set-up of the device, such as entering a
code or reading the display.
Ongoing Monitoring for Compliance
While in-person monitoring will be completed during the
initial sessions, subjects may be monitored and/or contacted
to confirm compliance throughout the remaining sessions.
Subject interaction will be maintained (e.g., through secure
video) to quantify compliance (device preparation, electrode
saturation/placement, stimulation protocol) with corresponding
corrective steps. As an example, secure video will be scheduled
and maintained with each subject daily. Visual confirmation
will ensure proper set up, appropriate home environment,
and acceptable impedance. Following these checks during
monitoring, subjects will be given their one time use code for that
session (Figure 7).
Ongoing Monitoring for Treatment-Emergent
Adverse Effects
Before starting a session, study staff will ask the subject about
any adverse events since the last session, with clearly defined
stop criteria if anything is reported that is of clinical concern
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FIGURE 6 | Guidelines for study equipment.
related to safety or tolerability. In addition, subjects will be asked
to report pain and/or discomfort level at set points during the
stimulation. If pain crosses a given threshold, there will be an
immediate stop in place in order to prevent any risk of skin burn
(Loo et al., 2011) and the supervising staff will assess whether
this has occurred due to suboptimal treatment technique. If tDCS
causes pain above the given threshold despite adequate treatment
technique, subjects will be withdrawn from the study. After the
session, subjects will be again assessed by study staff for any
adverse events. Subjects will also record their experience in the
study-specific materials.
Guidance to Identify and Implement
Discontinuation of a Session and/or Study
Participation (Including Emergency Failsafe
Procedures) Tailored to the Treatment
Population’s Level of Need
Finally, during training and in reference materials, subjects will
be instructed to abort the session if they need to immediately
discontinue stimulation by allowing ramp down and then
removing their headset. These instructions will be used if any
subject reports significant discomfort or other adverse event,
otherwise needs to discontinue a session, or if study staff
determines that the session should be discontinued.
Examples of Clinical Trial Applications and
Population-specific Adaptations
The authors’ interest in remote (non-clinic) tDCS for clinical trials
has facilitated effort to develop study protocols for specific patient
populations. Below, we provide examples of population-specific
considerations that may navigate tailoring the guidelines described
above to specific populations with differing limitations and needs.
These summaries are not intended to be exhaustive but rather
illustrate salient features of applying the above eight principles
to specific applications. Once population specific protocols have
been implemented, and the feasibility of these methods has been
confirmed within the target groups, more expansive clinical trials
can apply them to study the effectiveness of the treatment.
Attention Deficit Hyperactivity Disorder (ADHD)
The immediate facilitatory effects of tDCS on cognitive abilities
often seen impaired in ADHD has prompted interest in whether
or not the technique might have a therapeutic effect. For
instance, a recent study of ADHD-diagnosed children in another
experiment showed that 0.75 Hz oscillating tDCS increased EEG-
recorded slow wave oscillation during sleep, and subsequent
memory recall the next day (Prehn-Kristensen et al., 2014). One
brief tDCS trial in non-ADHD subjects showed better response
inhibition task performance after 5 consecutive days of training
with concurrent 1.5 mA anodal tDCS stimulation than training
alone (Ditye et al., 2012). The latter suggests that tDCS paired
with cognitive training/rehabilitation techniques might have
the highest potential for efficacy in minimizing ADHD-related
behavioral dysfunction. However, previous trials that combine
these therapeutic approaches typically last 1--3 weeks, making
clinic visits impractical for a typical family that contends with
school demands and extra-curricular activities, worsened when
there is more than one school-aged child in the home. Any
clinic-based tDCS trial for ADHD not only would be plagued
by poor compliance and high dropout, but it is also likely that
only the most motivated of families and subjects would complete
treatment, complicating generalizability and efficacy inferences.
Remotely-supervised tDCS performed is an obvious approach
to circumvent the main obstacles, but the age and behavioral
characteristics of the patient population introduce unique issues
to any home-based tDCS clinical trial. ADHD is a behavioral
disorder whose hallmarks are distractibility, restlessness, and
motivational issues--all of which must be managed effectively
within a standardized tDCS delivery protocol. Although
self-administered tDCS for adults diagnosed with ADHD
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FIGURE 7 | Guidelines for ongoing assessment.
certainly is feasible, it is more likely that trials will consider tDCS
with older children or adolescents, as tDCS has been shown
to be safe with these age groups. However, most institutional
review boards will not likely approve trial protocols where youth
are asked to set up and administer tDCS themselves, suggesting
effective trials must plan to overcome and troubleshoot issues
arising from parent training to administer tDCS properly. Such
issues include effective parent screening/training, attention
to how dyadic interactions influence motivation, and special
care in assessing compliance and outcome. To accommodate
these special considerations, we recommend a trial design that
at minimum includes: (1) a clinic visit for consent, clinical
assessment, and training with particular attention paid to
educating families that treatment must be a ‘‘whole family’’
cooperative effort, (2) an ‘‘at home’’ visit prior to treatment so
that research staff can assess and advise tDCS equipment set up
and other technical issues, (3) careful consideration of whether
every tDCS session should be remotely-supervised (e.g., via video
teleconferencing) to ensure optimal protocol adherence; and
(4) formal consideration in trial design of how ADHD-related
behavior interacts with both treatment delivery, motivation, or
outcome.
Some specific recommendations for ADHD protocols
include:
- Parent preparedness, training, and motivational issues:
Informed consent for a remotely-supervised tDCS trial
should emphasize the multiple types of training required for
parents who will administer tDCS. At minimum, parental
tDCS technical proficiency should be demonstrated as
suggested above, with at least 1 clinic visit and 1 remotely-
supervised session, if not at each daily session. If computer-
administered cognitive training techniques will accompany
tDCS stimulation, separate training should be provided in
how to start, stop, and evaluate the successful implementation
of such techniques. In addition, parent training should be
provided in how to properly motivate their ADHD-diagnosed
child. Obviously, an important goal is to avoid punitiveness
or coercion that might occur if parents are more motivated
than their children, but it is equally as important is to
standardize and measure motivation across the trial. For
example, simple behavioral contingency management
techniques should be considered as standard, especially for
younger age groups. Protocol-specific guidelines on how
and when to provide positive reinforcements should be
made explicit; their use should be quantified by trial staff
weekly.
- Dyadic interaction impact: It is not yet known what interaction
styles or personality factors might make some parents more
effective in operating and supervising tDCS at home than
others. Until such study has been done, we recommend that
each trial should make effort to formally assess the nature
of parent-child dyadic interactions or familial relationships
styles to see if they moderate treatment compliance or
outcome.
- Preparation for tDCS delivery and Monitoring of Potential
Treatment Barriers: Homes with children are different
than those without. For tDCS with a child or teenager,
tDCS should be set up in a specially-designated quiet
room and performed without distraction or interruption,
preferably with the cooperation of the whole family during
treatment delivery to reduce distractions. Protocols should
set clear guidelines for whether or not breaks are permitted
during training and set guidelines for them. A standardized
compliance checklist should be used for each session, which
emphasizes whether ADHD-related behaviors that could
have interfered with treatment occurred and how they were
managed. Any concurrently-done computer-administered
cognitive training ideally will be internet-enabled. This will
allow research staff to remotely verify that any exercises
were set up and run correctly, as well as offers the
potential for any behavioral performance data to be uploaded
for secure storage at the clinic site after each treatment
session.
Frontiers in Systems Neuroscience | www.frontiersin.org 9 March 2015 | Volume 9 | Article 26
Charvet et al. Remotely-supervised tDCS for clinical trials
- Careful Choice of Outcome Measures: Although it is likely that
the primary outcome measures of any tDCS trial would be
performance on tests of a specific cognitive domain, (either
because it is specifically targeted by concurrent cognitive
training or merely because it is one of several domains
often impaired in ADHD), secondary outcome measures
should include ADHD symptom severity checklists or ADHD
‘‘problem behavior’’ inventories (e.g., Brown ADD Scales).
Because of the subjective nature of the latter types of
assessments, it is important to use multiple respondents (e.g.,
parent and teacher). Similarly, the most effective trials will
include appropriate placebo conditions in order to mitigate
expectancy effects.
Depression
There is a long history of the use of ‘‘brain polarization’’,
essentially an earlier form of tDCS often given at lower stimulus
intensities, to treat depression (Arul-Anandam and Loo, 2009).
Over the last decade, in the context of the emergence of
brain stimulation treatments for depression (e.g., transcranial
magnetic stimulation) and developments in tDCS equipment,
methodology and scientific understanding, interest has rapidly
emerged in tDCS as a treatment for depression. tDCS has
been applied both to treatment resistant depression (i.e., in
subjects who have failed to improve after treatment with
antidepressant medication) and to non pharmacotherapy
resistant depression, as some patients may prefer a non
medication form of treatment. From 2006, evidence from several
placebo-controlled, randomized clinical trials has indicated
significant antidepressant effects for tDCS (Loo et al., 2012;
Brunoni et al., 2013a; Shiozawa et al., 2014). A key barrier to
the widespread use of tDCS for this common disorder is the
requirement to travel to a treatment center for multiple sessions
as repeated treatment sessions, typically given on consecutive
weekdays over several weeks, are often required to optimize
clinical response. For example, the Loo et al. (2012) study
suggested that extension of the treatment period from three to
6 weeks resulted in greater clinical improvement. After the acute
treatment course, ongoing ‘‘maintenance’’ tDCS, given weekly
to fortnightly, has also been reported to be useful in maintaining
improvement gained in the acute phase and preventing relapse
of depression (Martin et al., 2013a).
Several specific issues need to be considered when applying
tDCS in depression trials:
- An important precaution in this patient group is suicide risk,
which may fluctuate from day to day and should be closely
monitored. It is unknown if tDCS may lead to increased
suicide risk early in the treatment course (as has been proposed
with antidepressant medications), either due to improved
motivation, or specific treatment-related effects.
- Dose-control, i.e., control of access and restriction of
stimulation to pre-programmed stimulation is important as
a safeguard so that the device cannot be used for deliberate
self-harm.
- The research team should closely monitor fluctuations in
mental state, which may impinge on the subject’s ability
to adequately perform the tDCS procedure at home, for
example, due to changes in motivation or concentration.
Thus, it is possible that a subject initially assessed as
capable of performing remotely supervised tDCS at home,
later becomes unable to adequately continue treatment
at home---contingencies should be made for this event.
Conversely, given findings that tDCS improves information
processing speed in depressed patients (Loo et al., 2012) it
is also possible that subjects initially assessed as not capable
of performing remotely supervised tDCS at home, who may
need to commence acute treatment at the treatment center,
may later be able to continue the acute treatment course and
ongoing maintenance treatments at home under supervision.
- As part of the initial assessment of suitability for home-
based, remotely supervised tDCS, a thorough psychiatric
assessment by an experienced clinician is required, evaluating
not only mood, but also personality style, current stressors
and social and family support. All of these factors should
be considered in evaluating a person’s ability to comply
with tDCS procedures, likely fluctuations in mental state and
risk.
- The majority of depressed patients presenting for treatment
are likely to be on a combination of psychotropic medications,
including antidepressants, atypical antipsychotics, anxiolytics,
lithium and anticonvulsant mood stabilizers. Further,
alterations in concurrent medication treatment may occur
frequently common in order to manage side effects, achieve
better antidepressant response or provide symptomatic relief
(e.g., sleep, anxiety). As there is evidence that anticonvulsant
and benzodiazepine medications may affect the efficacy of
tDCS, these medications are best avoided if possible. The
tDCS team should maintain close liaison with the subject’s
treating doctor(s) throughout the tDCS treatment course, to
optimize concurrent medications and to establish procedures
for clear and prompt communication about any alterations in
medications.
Multiple Sclerosis (MS)
For those living with MS, treatments using tDCS have the
potential to directly alleviate common yet refractory symptoms
including pain, fatigue, depression, and sensory and motor
dysfunction (Palm et al., 2014). An important first step is
to establish the procedures for feasible at home use, with
consideration of potential motor and cognitive impairments.
For this patient population, the emphasis is on extensive
and ongoing screening procedures, as well as streamlined and
simplified equipment design and set up. To ensure compliance,
safety, and assist with training, a secure, daily video monitoring
protocol should be implemented.
Further recommendations for MS protocols include the
following:
- Screening is an important first step as remotely-supervised
tDCS will not be appropriate for all MS patients. A treating
neurologist should ensure that the subject has potential
suitability for operating the headgear and device. This
would include cutoffs for minimal neurological (motor) and
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cognitive function. For instance, severe motor impairment can
be screened for using the Expanded Disability Status Scale
(EDSS) score (Kurtzke, 1983), excluding those with scores of
6.5 or greater. In addition, subjects should be excluded from a
remotely-supervised protocol if any visual, auditory, or motor
deficits prevent the ability to understand the study instructions
or operate the device or laptop computer (Figures 1, 3).
Minimal cognitive ability for participation could also be
defined, for example by establishing cutoffs using the Brief
International Cognitive Assessment inMS (BICAMS; Benedict
et al., 2012) to exclude those with severe cognitive deficits.
- The study device should be simple to operate and engineered
to unlock single tDCS sessions through a one-time use
passcode. Headgear should also be simplified for use. For
example, headgear should be modified with a hat-like design
to ensureminimalmotor requirements. In addition, device kits
should be prepared and organized to ensure maximal ease in
terms of sponge pocket set-up and daily materials.
- Clinical and research staff should be trained through a study
technicianmanual on the device setup (programming sessions,
retrieving session codes), headgear placement, and subject
interactions (requirements for a successful session, items that
qualify as ‘‘stop’’ criteria, and troubleshooting). In addition,
research staff should be trained on how to safely abort a subject
session and on procedures to reestablish video connection if
lost.
- Subject training should occur during an initial in-person
training session where each subject will view an instructional
video, practice the technique in full and ultimately complete
their first tDCS session. Beyond training, these initial visits
will ensure inclusion and exclusion criteria are met. Subjects
must have a suitable home environment (e.g., distraction free
location and space to complete the sessions) access to internet,
and the ability to commit to tDCS sessions.
- An instructional video should support training and
implementation, be accessible to the subject throughout
the study, and cover all details necessary to complete a session.
The video should contain information on general materials, a
step by step guide to set up the device, how to abort a session
in case of emergency, and the means of properly ending a
session and disposing of materials.
- Stop criteria (assessed at baseline, during sessions, and at
follow-up) should be used as a gateway for the subject to
proceed at each step (Figure 3). The protocol should be
designed with a series of checkpoints to be met to address
compliance (attendance, ability to complete the procedures as
instructed, following study guidelines) and tolerability (at any
time if any predefined events are reported or if pain crosses a
threshold).
Palliative Care
Palliative care is an interdisciplinary model of care for patients
with serious or life-threatening illnesses. The goal of palliative
care is to manage symptoms of the disease and to mitigate
illness burden for the patient and family from the time of
diagnosis until the end of life. In the U.S., palliative care is
available through both hospital-based and community-based
palliative care programs (Hauser and Kramer, 2004; Defilippi
and Cameron, 2010; Connell et al., 2013; Kamal et al., 2013).
An overall goal of community-based palliative care is to provide
adequate support in symptom management, and psychological
and spiritual support to the patient and family so that the
patient can remain at home, even during the terminal phase of
the disease. Therefore, the development of novel home-based
approaches for symptom control is highly relevant for this patient
population.
Although outcomes targeted in existing tDCS studies, such
as pain, mood, sleep, cognitive performance, or overall quality
of life, are highly relevant for palliative care patients, there are
numerous barriers of an access of palliative care patients to
the tDCS studies. The burden of repeated visits to the research
facility in order to receive the tDCS application has been among
the major obstacles. Therefore, the development of the mini-CT
tDCS enabling home-application provides an opportunity for the
palliative care patients to be included in tDCS studies. However,
designing study protocols of remotely-supervised tDCS for
palliative care patients requires specific considerations, such as
the following:
- Involvement of family caregiver: Palliative care subjects
frequently rely on an assistance of family caregivers. Therefore,
it is likely that the home-based tDCS application will be
delivered by the family caregiver rather than self-performed
by the subject. Thus, both the subject and the family caregiver
may need to be included in the study.
- Minimizing burden to the subject and the family caregiver:
It has to be kept in mind that both the subject and the
caregiver bear the burden of the illness, and the level of
their overall distress may be high. Therefore, study procedures
pertaining to the tDCS procedure and data collection have to
be user friendly, easy and not time-demanding. Further, time
planning of study procedures should leave reasonable margins
acceptable for both the dyad of subject-caregiver and the study
personnel, for example when scheduling the real-time video
monitoring of the procedure. Further, it needs to be taken to
the account that the tDCS stimulation usually takes 15--20 min
during which the subject has to remain seated or in the bed,
without walking around. Therefore, subjects who for variety
of reasons, such as restlessness, are not comfortably able to
comply with that requirement are not good candidates for the
tDCS procedure. Another aspect to consider in this category
is data collection, especially in study population involving
palliative care subjects at advanced stage of the illness. While
data collection in healthy populations may include extensive
questionnaire sets and testing, data collection in palliative
care subjects should very carefully reflect the specifics of the
involved population.
- Polypharmacy: Symptom management in palliative care
frequently relies on pharmacological treatments, often
including multiple medications. There is growing evidence
indicating that certain agents (such as NMDA antagonists or
amphetamine) may alter (inhibit or enhance) tDCS effects.
This requires careful consideration when planning the tDCS
protocol, because it is unlikely that medication wash-out prior
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the study participation would be feasible in palliative care
patients.
- Feasibility: Overall, the feasibility of the home-delivered
remotely-monitored tDCS in palliative care patient population
is multifaceted, including (but not limited to) the following
elements:
- The patient’s and family caregiver’s understanding of the
procedure, their willingness and ability to participate in the
study.
- Caregiver’s ability to perform tDCS specific procedures
[after training]: Establishing videoconference connection;
Assembling the electrodes and the head set; Positioning the
headset on the subject’s head; Turning on-off the tDCS unit;
and the procedure has to be regarded by the involved caregiver
as acceptable for him/her and the subject;
- Subject’s acceptability and tolerability of the procedure: Able
to remain seated or in bed for the 20-min stimulation
[does not interrupt the stimulation session by walking
around]; Able to provide a brief feedback or numerical
rating when asked; Regards the procedure as acceptable;
Tolerates the tDCS procedure (in the means of adverse
events);
- Home environment: the Internet connectivity sufficient for the
videoconference connection; sufficient space to accommodate
the tDCS and videoconferencing devices.
Conclusion
Remotely-supervised tDCS can serve as an extension of in-clinic
administered tDCS sessions. Proper frameworks around clinical
staff training, user capability, training and monitoring guides are
intended to maintain the same level of safety and tolerability
experienced within the clinic setting. Careful consideration
of each of these criteria is essential to a remotely-supervised
trial. Future expansion toward a more robust training method
for clinical staff on the technique will further optimize its
application. In addition, following the completion of each clinical
trial, population-specific modifications will be considered within
the training, design, and monitoring of such patient populations.
For some subjects or populations, prescription for direct home
use may ultimately be the resulting clinical application, while
others may be eligible only for continued remotely-supervised
use. Validation of the compliance experienced in remotely-
supervised tDCS trials will serve as a means of comparison to the
level of compliance observed within in-clinic trials. Expanding
the patient populations able to comply with a tDCS trial through
remote supervision can ultimately broaden the reach of clinical
trials, helping to deepen the current understanding of tDCS.
With these principles in place, tDCS clinical trials will expand
with results to ultimately guide appropriate and effective clinical
use.
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